Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.63 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.63 |
| ▸ | MTOR | P42345 | 6/20 | 0.60 |
| ▸ | AKT1 | P31749 | 4/20 | 0.60 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10328142 | 0.91 | PIK3CA (0.71) | PIK3CAMAP3K12MTORAKT1PIK3R1 | |
| SCHEMBL17395961 | 0.87 | PIK3CA (0.58) | PIK3CAMAP3K12MTORAKT1PIK3R1 | |
| SCHEMBL10327733 | 0.86 | PIK3CA (0.65) | PIK3CAMAP3K12MTORAKT1PIK3R1 | |
| SCHEMBL17409344 | 0.85 | PIK3CA (0.57) | PIK3CAMAP3K12MTORAKT1PIK3R1 | |
| SCHEMBL4125040 | 0.83 | PIK3CA (0.69) | PIK3CAMAP3K12MTORAKT1PIK3R1 | |
| SCHEMBL10327966 | 0.83 | PIK3CA (0.84) | PIK3CAMAP3K12MTORAKT1PIK3R1 | |
| SCHEMBL17408883 | 0.82 | PIK3CA (0.50) | PIK3CAMAP3K12MTORAKT1PIK3R1 | |
| SCHEMBL10327622 | 0.81 | PIK3CA (0.78) | PIK3CAMAP3K12MTORAKT1PIK3R1 | |
| SCHEMBL10327577 | 0.81 | MTOR (0.68) | PIK3CAMTORPIK3R1PIK3CDPIK3CB | |
| SCHEMBL15014968 | 0.81 | PIK3CA (0.60) | PIK3CAMAP3K12MTORAKT1PIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563549-B2 | Pyrimidine derivatives used as PI-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| US-8563549-B2 | Pyrimidine derivatives used as PI-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-8217035-B2 | Pyrimidine derivatives used as PI-3-kinase inhibitors | NOVARTIS AG (CH) | 2012-07-10 | — | — | US | disclosed |
| US-8217035-B2 | Pyrimidine derivatives used as PI-3-kinase inhibitors | NOVARTIS AG (CH) | 2012-07-10 | — | — | US | disclosed |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | PIK3CA, PI4KA, PI4KB | PIK3CA 1/4885MAP3K12 125/4885MTOR 62/4885 |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | PIK3CA, PI4KA, PI4KB | PIK3CA 1/4885MAP3K12 129/4885MTOR 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.